Table 2.

Change in percentage of T cell markers and subsets from baseline to sirolimus treatment week 20 in the primary efficacy population (N = 16)

	CD8+ T cells		CD4+ T cells
	Mean (CI)	p	Mean (CI)	p
% PD-1+	−2.85 (−4.85, −0.86)	0.008a	0.42 (−1.81, 2.66)	0.69
% Ki67+	−0.54 (−0.90, −0.19)	0.005	−0.51 (−0.97, −0.05)	0.031
% CCR5+	−3.92 (−5.99, −1.85)	0.001	−1.67 (−3.76, 0.42)	0.11
% CD69+	−0.52 (−1.38, 0.35)	0.22	−0.17 (−0.97, 0.63)	0.65
% TNaïve	0.75 (−3.61, 5.12)	0.72	−2.16 (−5.46, 1.15)	0.18
% TCM	−0.87 (−1.82, 0.08)	0.07	−0.01 (−2.18, 2.17)	1.00
% TEM	−0.58 (−3.02, 1.86)	0.62	2.20 (−0.50, 4.90)	0.10
% TTD	0.68 (−2.82, 4.18)	0.69	−0.04 (−1.21, 1.14)	0.95

T_CM, central memory; T_EM, effector memory; T_TD, terminally differentiated.

^aFrom two-tailed, paired t tests.